European Union - English - EMA (European Medicines Agency)

sanofi pasteur europe - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of intanza should be based on official recommendations.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur msd ltd - human poliovirus type 3 inactivated; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; diphtheria toxoid; haemophilus influenzae type b polysaccharide protein conjugate - suspension for injection

European Union - English - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - hexyon (dtap-ipv-hb-hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib).the use of this vaccine should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

sanofi pasteur s.a. - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of idflu should be based on official recommendations.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur msd ltd - influenza virus split virion - suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur - rabies virus inactivated - powder and solvent for suspension for injection

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - tetanus toxoid, diphtheria toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3, adsorbed aluminium phosphate - suspension for injection - unknown - pertussis, purified antigen, combinations with toxoids

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - polio virus type 1 inactivated, polio virus type 2 inactivated, polio virus type 3 inactivated - suspension for injection - %v/v - poliomyelitis vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - haemophilus influenzae type b, conjugate with tetanus protein - pdr+solv for soln for inj - 10mcg/0.5m microgram/ml - hemophilus influenzae b vaccines

European Union - English - EMA (European Medicines Agency)

sanofi pasteur s.a. - split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a)*propagated in eggs. - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.